Literature DB >> 23966384

Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.

Erik R Hill1, Siva Koganti, Jizu Zhi, Cynthia Megyola, Alexandra F Freeman, Umaimainthan Palendira, Stuart G Tangye, Paul J Farrell, Sumita Bhaduri-McIntosh.   

Abstract

Lytic activation of Epstein-Barr virus (EBV) is central to its life cycle and to most EBV-related diseases. However, not every EBV-infected B cell is susceptible to lytic activation. This lack of uniform susceptibility to lytic activation also directly impacts the success of viral oncolytic therapy for EBV cancers, yet determinants of susceptibility to lytic induction signals are not well understood. To determine if host factors influence susceptibility to EBV lytic activation, we developed a technique to separate lytic from refractory cells and reported that EBV lytic activation occurs preferentially in cells with lower levels of signal transducer and activator of transcription 3 (STAT3). Using this tool to detect single cells, we now extend the correlation between STAT3 and lytic versus refractory states to EBV-infected circulating B cells in patients with primary EBV infection, leading us to investigate whether STAT3 controls susceptibility to EBV lytic activation. In loss-of-function and gain-of-function studies in EBV-positive B lymphoma and lymphoblastoid cells, we found that the levels of functional STAT3 regulate susceptibility to EBV lytic activation. This prompted us to identify a pool of candidate cellular genes that might be regulated by STAT3 to limit EBV lytic activation. From this pool, we confirmed increases in transcript levels in refractory cells of a set of genes known to participate in transcription repression. Taken together, our findings place STAT3 at a critical crossroads between EBV latency and lytic activation, processes fundamental to EBV lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23966384      PMCID: PMC3807321          DOI: 10.1128/JVI.01762-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Inhibition of the Epstein-Barr virus lytic cycle by protoapigenone.

Authors:  Chao-Ping Tung; Fang-Rong Chang; Yang-Chang Wu; Da-Wei Chuang; Attila Hunyadi; Shih-Tung Liu
Journal:  J Gen Virol       Date:  2011-04-13       Impact factor: 3.891

2.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis.

Authors:  Yassine Al Tabaa; Edouard Tuaillon; Eric Jeziorski; David Eric Ouedraogo; Karine Bolloré; Pierre-Alain Rubbo; Vincent Foulongne; Michel Rodière; Jean-Pierre Vendrell
Journal:  J Clin Virol       Date:  2011-09       Impact factor: 3.168

4.  Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.

Authors:  Derek Daigle; Cynthia Megyola; Ayman El-Guindy; Lyn Gradoville; David Tuck; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

5.  A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory.

Authors:  Andrea M Siegel; Jennifer Heimall; Alexandra F Freeman; Amy P Hsu; Erica Brittain; Jason M Brenchley; Daniel C Douek; Gary H Fahle; Jeffrey I Cohen; Steven M Holland; Joshua D Milner
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

6.  Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.

Authors:  De-Xue Fu; Yvette Tanhehco; Jianmeng Chen; Catherine A Foss; James J Fox; Ja-Mun Chong; Robert F Hobbs; Masashi Fukayama; George Sgouros; Jeanne Kowalski; Martin G Pomper; Richard F Ambinder
Journal:  Nat Med       Date:  2008-09-07       Impact factor: 53.440

7.  A user's guide to the encyclopedia of DNA elements (ENCODE).

Authors: 
Journal:  PLoS Biol       Date:  2011-04-19       Impact factor: 8.029

8.  A subset of replication proteins enhances origin recognition and lytic replication by the Epstein-Barr virus ZEBRA protein.

Authors:  Ayman El-Guindy; Lee Heston; George Miller
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

9.  Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines.

Authors:  Joyce Hui-Yuen; Shane McAllister; Siva Koganti; Erik Hill; Sumita Bhaduri-McIntosh
Journal:  J Vis Exp       Date:  2011-11-08       Impact factor: 1.355

10.  B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans.

Authors:  Danielle T Avery; Elissa K Deenick; Cindy S Ma; Santi Suryani; Nicholas Simpson; Gary Y Chew; Tyani D Chan; Umamainthan Palendira; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Sharon Choo; Karl E Bleasel; Jane Peake; Cecile King; Martyn A French; Dan Engelhard; Sami Al-Hajjar; Saleh Al-Muhsen; Klaus Magdorf; Joachim Roesler; Peter D Arkwright; Pravin Hissaria; D Sean Riminton; Melanie Wong; Robert Brink; David A Fulcher; Jean-Laurent Casanova; Matthew C Cook; Stuart G Tangye
Journal:  J Exp Med       Date:  2010-01-04       Impact factor: 14.307

View more
  26 in total

1.  B lymphocytes from patients with a hypomorphic mutation in STAT3 resist Epstein-Barr virus-driven cell proliferation.

Authors:  Siva Koganti; Amanda de la Paz; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

2.  STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation.

Authors:  Siva Koganti; Joyce Hui-Yuen; Shane McAllister; Benjamin Gardner; Friedrich Grasser; Umaimainthan Palendira; Stuart G Tangye; Alexandra F Freeman; Sumita Bhaduri-McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

3.  Retrograde Regulation by the Viral Protein Kinase Epigenetically Sustains the Epstein-Barr Virus Latency-to-Lytic Switch To Augment Virus Production.

Authors:  Xiaofan Li; Sergei V Kozlov; Ayman El-Guindy; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

4.  The replication and transcription activator of murine gammaherpesvirus 68 cooperatively enhances cytokine-activated, STAT3-mediated gene expression.

Authors:  Hui-Chen Chang Foreman; Julie Armstrong; Alexis L Santana; Laurie T Krug; Nancy C Reich
Journal:  J Biol Chem       Date:  2017-08-15       Impact factor: 5.157

5.  Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.

Authors:  Siva Koganti; Carissa Clark; Jizu Zhi; Xiaofan Li; Emily I Chen; Sharmistha Chakrabortty; Erik R Hill; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

6.  STAT3 Regulates Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Christine A King; Xiaofan Li; Arturo Barbachano-Guerrero; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

7.  Anti-TNFα therapy for inflammatory bowel diseases is associated with Epstein-Barr virus lytic activation.

Authors:  Sameer Lapsia; Siva Koganti; Salvatore Spadaro; Ramona Rajapakse; Anupama Chawla; Sumita Bhaduri-McIntosh
Journal:  J Med Virol       Date:  2015-08-31       Impact factor: 2.327

8.  KRAB-ZFP Repressors Enforce Quiescence of Oncogenic Human Herpesviruses.

Authors:  Xiaofan Li; Eric M Burton; Siva Koganti; Jizu Zhi; Francis Doyle; Scott A Tenenbaum; Biljana Horn; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 9.  The Dynamic Interface of Viruses with STATs.

Authors:  Angela R Harrison; Gregory W Moseley
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

10.  Human Cytomegalovirus Immediate-Early 1 Protein Rewires Upstream STAT3 to Downstream STAT1 Signaling Switching an IL6-Type to an IFNγ-Like Response.

Authors:  Thomas Harwardt; Simone Lukas; Marion Zenger; Tobias Reitberger; Daniela Danzer; Theresa Übner; Diane C Munday; Michael Nevels; Christina Paulus
Journal:  PLoS Pathog       Date:  2016-07-07       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.